quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:38:00·5d
PRRelease
Definium Therapeutics Inc. logo

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

DFTX· Definium Therapeutics Inc.
Health Care
Original source

Companies

  • DFTX
    Definium Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 17UpdateStifel$30.00
  • Apr 10UpdatePiper Sandler$49.00
  • Feb 24UpdateWolfe Research$25.00
  • Jan 30UpdateJefferies$30.00

Related

  • SEC1d
    Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR1d
    Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
  • PR3d
    Definium Therapeutics Announces New Employee Inducement Grants
  • ANALYST6d
    Stifel initiated coverage on Definium Therapeutics with a new price target
  • ANALYST13d
    Piper Sandler initiated coverage on Definium Therapeutics with a new price target
  • PR14d
    Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
  • PR23d
    New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
  • PR24d
    Definium Therapeutics Announces New Employee Inducement Grants
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022